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Abstract
Recent advances have shown impressive results by anti-interleukin 1 (IL-1) agents in refractory idiopathic recurrent pericarditis.
Purpose of Review
We critically discuss the current state of the art of therapy of relapsing pericarditis, with a focus on new pharmacological
approaches and on specific clinical settings such as pregnancy, pediatric patients, and secondary forms of relapsing pericarditis.
Recent Findings
Antagonism of the IL-1 is highly effective in idiopathic recurrent pericarditis with autoinflammatory features. Currently, avail-
able anti-IL-1 agents are anakinra and canakinumab. Rilonacept is another IL-1 antagonist, currently studied in the phase-3
clinical trial RHAPSODY. Available data suggest similar efficacy and safety profiles of these three agents, although only
anakinra has been tested in randomized clinical trials. These agents have slightly different pharmacological properties, being
canakinumab a specific IL-1ß antagonist while anakinra and rilonacept are unselective IL-1α and IL-1ß blockers. To date, there is
no evidence that specificity against IL-1ß affects safety and efficacy in patients with relapsing pericarditis, although it has been
proposed that unspecific blockage might be useful in severe disease.
Summary
Anakinra is the first anti-IL-1 agent with well-documented efficacy and safety in adult and pediatric patients with idiopathic
relapsing pericarditis. Other anti-IL-1 agents are currently under study. Future research should clarify the optimal duration of
therapy and tapering schedule of treatment with these agents. Moreover, biomarkers would be required to understand which
patients will benefit from early administration of IL-1 blockers due to refractoriness to conventional therapy and which others will
suffer from recurrences during the tapering of these agents. Lastly, future studies should focus on the subjects with the autoim-
mune or the pauci-inflammatory phenotype of idiopathic refractory pericarditis.
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Introduction
Pericarditis is an inflammatory disease of the pericardial sac
[1••]. According to the 2015 European Society of Cardiology
(ESC) guidelines for the diagnosis and management of peri-
cardial diseases [1••], recurrent pericarditis (RP) is defined as
the occurrence of two or more episodes of acute pericarditis
with an event-free period of at least 4–6 weeks. Up to 30% of
acute episodes recur within 18 months without adequate ther-
apy [2••], and about 10% of patients with RP experience re-
currences despite first- and second-line therapies, a condition
known as refractory recurrent pericarditis [1••, 3]. RP has a
good prognosis quoad vitam (i.e., scarce disease-related
mortality), although the quality of life (QoL) may be
severely affected, especially in patients with frequent
relapses or juvenile onset [1••]. Refractory RP repre-
sents a therapeutic challenge and is experiencing impor-
tant advances in disease therapy.
Treatment of acute pericarditis should target the underlying
etiology, whenever this can be identified. Most frequent etiol-
ogies show geographical variation and differ between RP and
the first episode of acute pericarditis. In developed countries,
most cases of RP are labeled as “idiopathic” RP (IRP) as no
obvious etiologies can be identified after an exhaustive
screening [1••, 4•]. We highlight that significant disease het-
erogeneity is present among subjects with IRP, requiring a
tailored therapeutic approach. Based on clinical patterns and
response to therapy, three main phenotypes of IRP can be
recognized [4•]:
1. An autoimmune phenotype, characterized by subacute
course, moderate C-reactive protein (CRP) elevation, fre-
quent autoantibody positivity (anti-nuclear antibodies
(ANA), anti-heart antibodies (AHA), anti-intercalated
disk autoantibodies (AIDA)), and features occurring in
systemic autoimmune diseases (e.g., arthralgias, dry eyes,
Raynaud’s phenomenon).
2. An autoinflammatory phenotype, characterized by recur-
rent relapses followed by complete resolution, highly
symptomatic serositis, strikingly high CRP, and high fe-
ver. Autoantibodies are frequently absent.
3. An aspecific phenotype, characterized by mildly symp-
tomatic patients with few attacks, subacute course, smol-
dering elevation of inflammatory markers, no evidence of
autoimmunity.
It is proposed that relevant pathogenic differences underlay
these phenotypic heterogeneities. Indeed, studies have shown
that IRP-associated inflammation might be driven by autoim-
mune and/or autoinflammatory mechanisms [4•] .
Autoimmunity is suggested by the occurrence of RP in many
systemic autoimmune diseases and by the detection of high
titers of AHA and AIDA in up to 67.5% of IRP patients [5•].
However, the mere presence of autoantibodies does not defin-
itively prove a pathogenic role of autoimmunity, as they may
be an epiphenomenon of pericardial inflammation. Intrinsic
dysregulation of innate immunity (i.e., auto-inflammation) is
suggested by familiar aggregation and similarities with some
autoinflammatory diseases, such as Familial Mediterranean
Fever (FMF), or tumor necrosis factor receptor-associated
periodic syndrome (TRAPS). Similarly to patients with
FMF and TRAPS, patients with the autoinflammatory phe-
notype of IRP respond spectacularly to anti-interleukin-1
(IL-1) agents.
IL-1 is one of the major inflammatory cytokines: two dif-
ferent proteins belonging to this same family have been iden-
tified in 1985, IL-1α and IL-1β, and have since been widely
studied in relation to their proinflammatory and pyrogenic
properties [6, 7]. IL-1α is constitutively present in every
healthy cell type, whereas IL-1β is produced by leukocytes
upon stimulation [8]. IL-1β upregulates inflammatory media-
tors such as cyclo-oxygenase-2 (COX-2) and prostaglandins
(PG) and can drive hyperemia, edema, and hyperesthesia—all
features of pericardial inflammation [9]. Multiple stimuli re-
sult in IL-1 production, including pathogen-associated molec-
ular patterns (PAMPs), damage-associated molecular patterns
(DAMPs), and other inflammatory cytokines such as TNFα,
IL-18, or IL-1β itself, spiraling in a vicious circle of
autoinflammation [8].
Here, we review current pharmacological management of
IRP—with a specific focus on recent advances represented by
the advent of anti-IL1 agents in the field- and of specific clin-
ical settings including pediatric or pregnant patients and RP
secondary to post-cardiac injury, systemic autoimmune, or
autoinflammatory diseases. The pathogenesis of IRP and po-
tential pharmacological targets are shown in Fig. 1.
Specific complications of pericarditis such as cardiac
tamponade and development of pericardial constriction may
require interventional therapy and are beyond the scope of this
review.
Therapy of Idiopathic Recurrent Pericarditis
The goals of RP treatment are (i) management of the acute
episodes with the induction of remission and (ii) prevention of
recurrences. Patients with pericarditis can usually be treated as
an outpatient, except for those at high risk that require hospital
treatment [1••].
First-line therapy of recurrences of IRP treatment does not
differ from that for the first episode of acute idiopathic peri-
carditis, although it should be tapered more slowly: high-dose
acetylsalicylic acid (ASA) or non-steroidal anti-inflammatory
drugs (NSAIDs) and colchicine are the mainstays of therapy
[1••]. The choice of the specific NSAID to use should be
guided by patient’s comorbidities, allergies, tolerance to treat-
ment, and Physician’s experience [1••, 10]. NSAID should be
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prescribed at the greatest tolerable dosage; severe cases
may require IV administration to control pain and a more
rapid induction of remission. Colchicine has been proven
to be safe and effective in reducing symptoms duration,
recurrences, and hospitalization rate [2••, 11–13]. Despite
the combination of colchicine and high-dose NSAIDs,
recurrences occur in more than 20% of patients [14].
Low to moderate doses of corticosteroids (e.g., predni-
sone 0.2–0.5 mg/kg × day) can be considered in subjects
of incomplete response to NSAIDs and colchicine (triple
therapy) or with intolerance/contraindications to NSAIDs
(e.g., allergy, pregnancy, bleeding risk) [1••]. Steroid ta-
pering should be very slow to avoid recurrences. High-
dose corticosteroids (e.g., prednisone 1 to 1.5 mg/kg/day)
should not be prescribed in IRP because it is suspected to
increase the steroid dependency of these patients [12,
15–17]. Lifestyle interventions should overlap pharmaco-
logical therapy of IRP but are beyond the scope of this
review. Table 1 shows first- and second-line approaches
to uncomplicated recurrent pericarditis.
Third-Line Treatment and Novel
Immunotherapies
Immunosuppressive Agents and Intravenous
Immunoglobulins
Since 1987 [14], immunosuppressive agents have been used as
third-line therapy for refractory IRP, often in combination with
corticosteroids. The most widely used drug is azathioprine at
the dose of 2 mg/kg die [18, 19]. Azathioprine is a slow-acting
corticosteroid-sparing agent that may help in the long term.
Little data are available regarding other immunosuppressive
agents for RP (e.g., cyclophosphamide, methotrexate, cyclo-
sporine, mycophenolate, and hydroxychloroquine) [18, 20•].
Small case series suggest that intravenous immunoglobu-
lins (IVIGs, 400–500 mg/kg for 5 days, potentially followed
by an additional cycle 1 after 1 month) might be effective in
refractory IRP during the acute phase [21, 22]. Since the ad-
vent of anti-IL1 therapies, the role of immunosuppressive
agents and IGIV has much reduced, being mostly confined
Fig. 1 Pathogenesis of IRP and
potential pharmacological targets.
DAMP damage-associated
molecular pattern, PAMP
pathogens-associate molecular
patterns, TLR Toll-like receptor,
NLR nod-like receptor, APC
antigen-presenting cell, Ly
lymphocytes, AHA anti-heart
antibodies, AIDA anti-
intercalated-disk antibodies, PL-
A2 phospholipase-A2, COX-1
cyclooxygenase-1, TNF tumor
necrosis factor, IL interleukin, IL-
1RA interleukin 1 receptor
antagonist, IL-1R interleukin 1
receptor, NSAID nonsteroidal
anti-inflammatory drugs, NFkB
nuclear factor k-light-chain-
enhancer of activated B cells
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to RP associated with systemic autoimmune diseases or in
some patients IRP with an autoimmune phenotype.
Anti-IL-1 Therapies
The most striking advances in the last years include the rec-
ognition of the impressive results of anti-IL-1 agents for re-
fractory IRP (Table 2). Available IL-1 antagonists include
anakinra and canakinumab [1••], while rilonacept is a third
molecule currently being studied on IRP patients by a phase
2 trial. These agents are self-administered by patients by a
subcutaneous injection.
Anakinra
Anakinra is a recombinant non-glycosylated homolog of hu-
man IL-1 receptor antagonist (IL-1RA) that competitively in-
hibits IL-1α and IL-1β binding to the IL-1 receptor. Anakinra
has a short half-life (4–6 h), with rapid recovery of immune
function and very low risk of severe infections [32]. The most
frequent adverse effects are injection-site reactions, which
usually occur after the first week and tend to subside by the
first month of therapy. No dose adjustment is required based
on BMI, age, or gender [33, 34]. Plasma clearance of anakinra
occurs predominantly via the kidneys. However, no dose
adjustment is needed for patients with mild renal impairment
(GFR > 50 ml/min × 1.73 m2) [32], whereas dose or schedule
adjustment is indicated for patients with severe renal impair-
ment or end-stage renal disease [33]. Although it has been
shown that anakinra therapy induces anti-drug antibodies
(ADA), this was not associated with any clinically significant
effects on PK, efficacy, or safety [35]. Anakinra is well toler-
ated, with injection site reactions (ISRs) being the most com-
mon adverse event; experienced in up to 70% of patients
(however, 95% of cases are mild to moderate in severity).
Clinical experiences indicated that there are two different
types of ISRs in relation to injections of anakinra: immediate
burning feeling and delayed erythema with pruritus, swelling,
and pain [36]. To alleviate the acute burning, it is advised to
warm the syringe to room temperature before the injection and
to apply a cold pack to the injection site 2–3 min before and
immediately after the injection. The delayed reactions can be
mitigated and treated by the application of topical hydrocorti-
sone or anti-histamine cream [36]. In most cases, ISR disap-
pears within 2 months. However, these reactions may impact
on adherence to therapy and patients should be informed in
advance about these non-severe and transient skin reactions.
Anakinra is contraindicated in patients with known hyper-
sensitivity to E. coli-derived proteins or any components of
the product. An increased risk of reactivation of latent tuber-
culosis (LTB) has been described for patients on biologics,
Table 1 Standard pharmacological approach to uncomplicated recurrent pericarditis
Drug Initial dose Tapering Therapy duration
First-line therapya
Level of evidence: A
Aspirin 500–1000 mg every 8 h (1500–3000 mg daily) Following the resolution of symptoms, decrease the total daily dose
by 250–500 mg weekly over 2 to 4 weeks in an attempt to
reduce the subsequent recurrence rate
Weeks-months
Ibuprofen 600–800 mg every 8 h (1800–2400 mg daily) Following the resolution of symptoms, decrease the total daily dose
by 200–400 mg weekly for 2 to 4 weeks in an attempt to reduce
the subsequent recurrence rate
Weeks-months
Indomethacin 25–50 mg every 8 h (75–150 mg daily) Following the resolution of symptoms, decrease the total daily dose
by 25 mg weekly for 2 to 4 weeks in an attempt to reduce the
subsequent recurrence rate
Weeks-months
Naproxen** 250–500 mg every 12 h; maximal daily dose
1500 mg for limited time period (< 6 months)
Following the resolution of symptoms, decrease the total daily dose
by 125–250 mg every 1–2 week
Weeks-months
Colchicine 0.6 mg twice daily or 0.6 mg once daily for patients
< 70 kg or with chronic kidney disease
Gradual tapering off At least 6 months
Second-line therapyb
Level of evidence: B
Prednisone 0.2 to 0.5 mg/kg/daily After resolution of symptoms and CRP normalization according to
the following schedule: > 50 mg = 10 mg/day every 1–2 weeks
25–50 mg = 5–10 mg/day every 1–2 weeks
15–25 mg = 2.5 mg/day every 2–4 weeks
< 15 mg = 1.25–2.5 mg/day every 2–6 weeks
Months
a Aspirin or NSAIDS + colchicine
b Low-dose corticosteroids (added at low to moderate doses to aspirin/NSAIDs and colchicine as triple therapy)
*For all drugs: monitoring based on the assessment of blood count, creatinine, transaminases, C-reactive protein, echocardiography
**Dosage expressed as naproxen base; 200 mg naproxen base is equivalent to 220 mg naproxen sodium
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although anakinra and IL1 might confer only moderate risk.
However, LTB screening is recommended before beginning
therapy and, for some authors, also annually [37]. Clinicians
should follow local guidelines at the purpose, such as those
provided by the Centers for Disease Control and Prevention
(CDC) for screening and prophylaxis of LTB.
Anakinra has been widely used in cardiovascular settings
to tackle conditions such as pericardial disease, heart failure,
coronary artery disease, and myocardial infarction [9, 24, 28,
38]. After the first reports and case series, anakinra (100 mg
die) was studied in a double-blind, placebo-controlled trial in
patients with colchicine-resistant and corticosteroid-
dependent IRP (the AIRTRIP trial) [39••]. In this study,
90% of patients treated with conventional agent group faced
a relapse vs 18% in the anakinra group. A recent retrospective
study on seven patients with refractory IRP suggests that
anakinra is rapidly effective even in corticosteroid-dependent
patients with IRP refractory to conventional therapy and also
to third-line agents such as AZA and IVIG [28]. A real-life
study on an international registry analyzing data from 224
patients with refractory IRP on anakinra showed that anakinra
confers a six-fold reduction in recurrences, an 11-fold reduc-
tion in ER admissions, and a 7-fold reduction in hospitaliza-
tions [40•]. Anakinra was generally well tolerated, resulted in
lower steroid use and did not associate with serious adverse
events: only 3% of patients discontinued anakinra due to ad-
verse effects. Three patients (14%) experienced mild and tran-
sient transaminase elevation in the AIRTRIP trial [39••] [40•].
In case series of IRP reviewed by Baskar et al., anakinra gave
transient transaminase elevation in 10–30% of patients [41•].
Real-life data [40•] provide insight on IRP recurrences dur-
ing or after anakinra discontinuation: a higher risk of relapse
was seen in patients with a less than a 3-month period on full-
dose anakinra treatment before tapering and in those with a
tapering scheme shorter than 3 months. The mean time to
recurrences increased from 157 days to almost 1000 days in
patients on anakinra, implying great disease control and less
indirect costs (hospitalizations, school/work absence, steroid
side effects management) [40•]. We suggest to follow a very
slow tapering of anakinra by progressively discontinuing drug
administration in individual days. In the case of relapses
during tapering, we maintain the lowest effective dose.
In conclusion, anakinra is safe and effective for refrac-
tory IRP, especially in the case of an autoinflammatory
phenotype [8, 42].
Canakinumab
Canakinumab is a human monoclonal antibody anti-IL-1β. It
has a long half-life of ~ 22–26 days and can be administered
every 4–8 weeks. After correction for body weight, no clini-
cally significant disease status, gender, or age-relatedTa
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differences in pharmacokinetics were observed among patients
affected by various inflammatory diseases. Therefore, a fixed
dosage of 150 mg/month is prescribed to adult patients.
A pilot study in 2017 proved canakinumab efficacy in re-
ducing cardiovascular events in secondary prevention [43].
Moreover, canakinumab is the only IL-1 inhibitor approved
for the treatment of various autoinflammatory diseases (col-
chicine-resistant FMF, TRAPS, cryopyrin-associated periodic
syndrome [CAPS], and gouty arthritis) and in systemic-onset
juvenile idiopathic arthritis (so-JIA) [27, 29, 44].
Canakinumab has limited use in pericarditis due to very high
costs is limited to case report and series [45]. A case series on
patients with IRP experiencing injection-site reactions to
anakinra suggested the efficacy of canakinumab [46]. In an-
other report of a pediatric patient suffering from IRP,
canakinumab was effective in controlling disease recurrences,
although an anaphylactic reaction occurred [47]. In conclu-
sion, canakinumab might be considered in subjects allergic
or intolerant to anakinra, although its cost is very high.
Rilonacept
Rilonacept, known as “IL-1 trap,” is a dimeric fusion protein
consisting of the ligand-binding domains of IL-1R and IL-1
receptor accessory protein (IL-1RAP) linked in-line to the Fc
portion of human IgG1. Consequently, rilonacept binds to
and blocks the activity of IL-1α and IL-1β. Rilonacept also
binds the endogenous IL-1RA but with a lower affinity than
IL-1β or IL-1α. Based on limited data, steady-state trough
concentrations were similar between male and female pa-
tients, and scarcely affected by age and body weight. Thus,
rilonacept is prescribed at the fixed dose of 160 mg per week
by subcutaneous administration. Impaired liver and renal
function do not affect pharmacokinetics in a clinically sig-
nificant way [48]. ADA were detected in 35% of patients,
although there was no correlation of antibody activity with
either clinical efficacy or safety. Rilonacept was generally
well tolerated. The most common adverse events were mild
injection site reactions; however, a transient skin abscess
resulting in rilonacept discontinuation has been reported in
one patient (4%), in a multicenter Phase 2 Clinical Trial
enrolling 25 adults with RP [49•]. Rilonacept has been given
the “orphan drug” status by the FDA for the treatment of
CAPS, since it grants significant improvement of symptoms
and normalization of serum amyloid A (SAA) levels with
good safety and tolerability profile [25, 31]. Also, it has been
successfully tested in the prevention of gout flares, but the
FDA rejected its enlistment among gout drugs for lack of
long-term safety and efficacy data and economic sustainabil-
ity [50]. A RCT proved its efficacy in systemic-onset juve-
nile idiopathic arthritis [51]. In 2019, the FDA granted
rilonacept the “Breakthrough Therapy” status, based on
results from an open-label phase 2 trial that provided the first
evidence of rilonacept efficacy and safety in IRP patients
[49•]. The authors reported a reduction of recurrences, lower
steroid requirements, and improved life quality in all types of
patients, ranging from symptomatic IRP to asymptomatic
corticosteroid-dependent IRP. Patients belonging to the first
category reported a reduction both in pain, inflammation,
and pericardial signs of pericarditis, whereas all patients on
corticosteroids stopped them without experiencing relapses
during the 18 extension weeks. Adverse events occurred in
13 subjects (9/13 drug-related), most commonly mild tran-
sient injection site reactions (no discontinuations) [49•].
Currently, rilonacept is now under investigation in
phase 3 clinical trial RHAPSODY (NCT03737110), in
IRP patients with at least three pericarditis recurrences
while receiving any combination of first- and second-
line therapy. In the RHAPSODY trial, a single-blinded
period of rilonacept administration (320 mg loading
dose and 160 mg sc weekly, with concomitant tapering
of other therapies) is followed by a double-blinded
withdrawal randomization in either rilonacept or placebo
for 24 weeks. This study is estimated to be completed
by June 2021.
Comparing Anakinra, Canakinumab, and Rilonacept
According to available data, efficacy and safety profiles
of anakinra, canakinumab, and rilonacept seem similar.
All of these three agents require subcutaneous administra-
tion. The short half-life of anakinra results in daily sub-
cutaneous administration and a higher potential safety in
the case of concomitant serious infection. Rilonacept re-
quires weekly administrations while canakinumab only
once a month. In the IRP setting, anakinra is the only
drug with supporting evidence coming from randomized
clinical trials. To date, there is no evidence that selective
antagonism of IL-1β might be less effective and safer
than unselective antagonism of IL-1α and IL-1β.
However, some experts have suggested that blocking both
IL-1α and IL-1β might be useful in severe cases; on the
other hand, it is reasonable to expect a better compliance
in patients treated with canakinumab due to easier admin-
istration schedule.
While NSAIDs, colchicine and steroids are very
cheap, a disadvantage of anti-IL therapy is high cost:
canakinumab is the least affordable of these drugs,
while anakinra is the cheapest (with an ex-factory price
of about 930€/1060$ per month). To date, there are no
cost-effectiveness data of anti-IL1 agents as compared
to traditional therapy in IRP. Thus, we suggest to limit
their prescription to cases in which first- and second-
line agents result in suboptimal disease control.
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Specific Clinical Settings
Pediatric Population
About 5% of chest pain in children (mostly male adolescents)
is caused by pericarditis [52•, 53]. The autoinflammatory phe-
notype of pediatric pericarditis is more frequent than in adult
patients. Since specific etiologies are more frequent in chil-
dren suffering from RP, a genetic screening for FMF or
TRAPS is often proposed in case of periodic fever history or
familiarity for RP or autoinflammatory disorders [4•]. Very
little specific evidence is available for pediatric patients.
Regarding traditional therapy, ASA is not recommended in
order to avoid Reye syndrome. Corticosteroids should be
avoided as much as possible due to its side effects (e.g.,
growth retardation, pediatric obesity) [1••, 15, 54–56].
Regarding anti-IL1 agents, the long-term use of anakinra in
monotherapy was associated with persistent control of RP in
12 children enrolled in a multicenter retrospective study by
Finetti et al. [57]. In line with this, a pediatric case of steroid-
dependent RP, with a dramatic therapeutic response to
anakinra but without response to canakinumab has been re-
cently reported [58]. Given anakinra safety and efficacy in
children with autoinflammatory diseases and in pediatric case
series of refractory IRP [39, 59•, 60], it might be rational to use
anakinra earlier than in adult patients (e.g., as a second-line
therapy or after a lower number or relapses). Anakinra doses
require adjustments in these patients (see Table 2).
Pregnancy
Pericardial diseases during pregnancy are rare and little evi-
dence is available for this setting. Observational studies have
reported a good outcome for women and infants [61•].
NSAIDs require a gradual tapering until gestational week
20, due to the increased risk of constriction of the ductus
arteriosus and impaired fetal renal function; NSAIDs must
be stopped before gestational week 32 [62]. Prednisone, pred-
nisolone, and methylprednisolone may be used during all
pregnancy at low-dose since they are metabolized by the pla-
centa into inactive forms [62]. Low-dose colchicine has been
safely used in women with FMF during pregnancy and
breastfeeding, and it can be suggested also in RP pregnant
patients [61•, 63]. Little evidence is available about anakinra
safety during pregnancy and lactation. The current recommen-
dation is to discontinue this medication prior to pregnancy
given the lack of safety evidence [63] and to discontinue
breast-feeding during treatment with anakinra [64].
However, IL-RA is a normal component of human milk and
a small retrospective series documented positive maternal and
fetal outcomes of 43 pregnancies maternally exposed to anti-
IL1 agents.
Post-Cardiac Injury Syndromes
Post-cardiac injury syndromes include pleuro-pericarditis occur-
ring after myocardial infarction, chest trauma, cardiac surgery,
and percutaneous procedures. Once elicited, pleuropericarditis
can be monophasic or recurrent. Pathogenesis is poorly under-
stood, although it is likely to include autoinflammation and au-
toimmunity similarly to IRP [65]. Accordingly, post-cardiac in-
jury recurrent pericarditis can be management similarly to IRP,
as recently reviewed by Verma et al. [65].
Autoimmune Diseases
Cardiac involvement is very common in autoimmune disor-
ders such as SLE, RA, SS, Still disease, rheumatic
polymyalgia, and vasculitis (e.g., Behcet’s disease, giant cell
arteritis, Takayasu arteritis) [66–69]. Pericarditis relapses of-
ten overlap with flares of the underlying condition, which
represent the main focus of therapy. In some cases, RP repre-
sents the main clinical feature and it may be less clear whether
therapy should focus on RP or follow the standard of care for
the underlying condition, considering pericarditis as an epi-
phenomenon. It is reasonable to assume that the correct ap-
proach lies in the middle, but nowadays, there is no consensus
about any therapeutic algorithm. As a general indication,
NSAIDS, colchicine, and corticosteroids might be used for
acute management of pericarditis unless contraindicated, al-
though immunosuppressive agents are typically required [1•,
23, 70–73]. Anti-IL-1 immunotherapies must be carefully
considered in these patients. However, IL-6 signaling block-
ade by tocilizumab has been used in many autoimmune con-
ditions such as RA, adult-onset Still disease, Takayasu arter-
itis, and associated concomitant RP [23, 26, 30, 74, 75].
Interestingly, Lee et al. investigated whether anakinra could
block Lactobacillus casei cell wall extract (LCWE)-induced
coronary lesions, in an established mouse model of Kawasaki
disease (KD) [76]. They found that these lesions can efficient-
ly be prevented by anakinra, providing both innovative cellu-
lar and molecular mechanistic insights and novel therapeutic
strategies to prevent the development of coronary lesions.
Furthermore, anakinra was effective in a patient with fulmi-
nant viral myocarditis, suggesting that anakinra may represent
a promising candidate for the treatment of inflammatory heart
failure [77].
Autoinflammatory Diseases
RP is frequent in many autoinflammatory diseases, including
FMF and TRAPS. RP in these patients should be considered
as a red flag for poorly controlled disease and treated accord-
ingly: FMF patients should be managed with up-titration of
colchicine or with anti-IL1 therapies [78], while TRAPS pa-
tients should be offered biologic therapy [79].
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Other Possible Biological Therapies
IL-6 is another pivotal inflammatory cytokine. High
levels of IL-6 have been demonstrated in the pericardial
fluid compared to serum, suggesting that IL-6 is locally
produced and might concur in driving pericardial inflam-
mation. Their subjects have been reported to be success-
fully treated with tocilizumab for refractory pericardial
effusions with RA and a further patient for refractory
SLE-associated pericarditis [80–82]. A recent case of
successful treatment of SLE-associated pleuritis with
tocilizumab was also reported [83]. Further studies are
required to assess whether IL-6 might have a role in IRP.
Myopericarditis has been described in the current pandem-
ic of coronavirus disease 2019 (COVID-19) [84]. Severe
COVID-19 is characterized by hyperinflammation potentially
due to a cytokine storm syndrome [85]. Randomized clinical
trials, such as the AMMURAVID trial, are ongoing to verify
anti-cytokine agents blocking IL-1 and IL-6might be effective
also in this condition.
Conclusions
IRP has primarily an autoinflammatory and/or autoim-
mune etiology. Management is based on high-dose
NSAIDs and colchicine and low to moderate dose of
corticosteroids in the case of suboptimal disease control.
The IL-1 pathway has emerged as pivotal in the patho-
genesis of IRP, and anti-IL-1 agents have been proven
to be highly effective in patients with refractory IRP
and autoinflammatory features.
Future studies should clarify the optimal duration and
tapering schedule of treatment with these agents.
Moreover, biomarker studies would be required to under-
stand which patients will experience refractory disease
requiring anti-IL-1 therapy and which others will suffer
from recurrences during the tapering of these agents, in
order to allow a more efficient and personalized therapy.
Lastly, most of the recent advances have involved patients
with highly inflammatory RP. Future studies should focus
also on the subjects with the autoimmune or the pauci-
inflammatory phenotype of IRP.
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